Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779914 | 0.78 | CNR1 (0.44) | CNR1HTTCNR2 | |
| SCHEMBL4284498 | 0.77 | ALDH1A1 (0.53) | HTTALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL4284552 | 0.75 | LMNA (0.45) | HTTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL13148083 | 0.74 | CSF1R (0.61) | ALDH1A1KMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL13543760 | 0.74 | SLC6A2 (0.40) | ALDH1A1POLBL3MBTL1 | |
| SCHEMBL28500909 | 0.74 | MAPT (0.57) | HTTALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL4281475 | 0.73 | HPGD (0.53) | HTTALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL28905597 | 0.72 | MAPT (0.56) | HTTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL13594762 | 0.71 | LMNA (0.50) | — | |
| SCHEMBL13544467 | 0.71 | L3MBTL1 (0.43) | ALDH1A1KMT2AMEN1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20100021420-A1 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | ASTEX THERAPEUTICS LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| EP-2046330-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-2046327-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-2043635-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-2026805-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | Astex Therapeutics Limited (GB) | 2009-02-25 | — | — | EP | disclosed |
| EP-2027109-A1 | 4- (2, 6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-S-CARBOXYLIC ACID (1-METHANESULPH0NYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | Astex Therapeutics Limited (GB) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008009954-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008007122-A2 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008001101-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007129066-A1 | 4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129062-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | CDK1, CCNO, CDK14 | CNR1 253/4885HTT 1292/4885ALDH1A1 3995/4885 |
| US-20100021420-A1 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | CDK9, CDK1, CDK19 | CNR1 855/4885HTT 3971/4885ALDH1A1 3152/4885 |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA5A, PDK4 | CNR1 242/4885HTT 2605/4885ALDH1A1 95/4885 |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | CDK1, CDK4, CDK3 | CNR1 1154/4885HTT 3508/4885ALDH1A1 2379/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | CNR1 1271/4885HTT 2532/4885ALDH1A1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.